| Term 
 
        |         Alkylating Agents Nitrogen Mustards |  | Definition 
 
        | Cyclophosphamide (Cytoxan®) Ifosfamide (Ifex®) Mechlorethamine (Mustargen®) Melphalan (Alkeran®) Chlorambucil (Leukeran®) Estramustine (Emcyt®)   MOA: Alkylates and crosslinks DNA |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Cytoxan®           Nitrogen Mustard (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Ifex®           Nitrogen Mustard (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Mustargen®           Nitrogen Mustard (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Alkeran®           Nitrogen Mustard (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Leukeran®           Nitrogen Mustard (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Emcyt®           Nitrogen Mustard (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 
        |         Alkylating Agents Nitrosoureas |  | Definition 
 
        | Carmustine (BiCNU®) Lomustine (CeeNU®) Streptozocin (Zanosar®)     MOA: Alkylates and crosslinks DNA |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | BiCNU®           Nitrosourea (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CeeNU®           Nitrosourea (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Zanosar®           Nitrosourea (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 
        |       Alkylating Agents Platinum Analogs |  | Definition 
 
        | Cisplatin (Platinol®) Carboplatin (Paraplatin®) Oxaliplatin (Eloxatin®)     MOA: Binds and crosslinks DNA |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Platinol®           Platinum Analog (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Paraplatin®           Platinum Analog (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Eloxatin®           Platinum Analog (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Busulfan (Myleran®) Thiotepa Procarbazine (Matulane®) Dacarbazine (DTIC-Dome®) Temozolomide (Temodar®)     MOA: Binds and crosslinks DNA |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Myleran®             Other (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | No Brand Name           Other (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Matulane®           Other (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | DTIC-Dome®           Other (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Temodar®           Other (Alkylating Agent) |  | 
        |  | 
        
        | Term 
 
        |       Antimetabolites Folate Analogs |  | Definition 
 
        | Methotrexate (Rheumatrex®) Pemetrexed (Alimta®)       MOA: Inhibits dihydrofolate reductase and lymphocyte proliferation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Rhematrex®, Trexall®             Folate Analog (Antimetabolite) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Alimta®           Folate Analog (Antimetabolite) |  | 
        |  | 
        
        | Term 
 
        |       Antimetabolites Pyrimidine Analogs |  | Definition 
 
        | 5-Fluorouracil (Efudex®) Cytarabine (Cytosar-C®) Gemcitabine (Gemzar®) Capecitabine (Xeloda®) Azacitidine (Vidaza®)     MOA: Inhibits DNA and RNA synthesis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Efudex®, Adrucil®           Pyrimidine Analog (Antimetabolite) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Cytosar-C®, Ara-C           Pyrimidine Analog (Antimetabolite) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Gemzar®           Pyrimidine Analog (Antimetabolite) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Xeloda®           Pyrimidine Analog (Antimetabolite) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Vidaza®           Pyrimidine Analog (Antimetabolite) |  | 
        |  | 
        
        | Term 
 
        |       Antimetabolites Purine Analogs |  | Definition 
 
        | 6-Mercaptopurine (Purinethol®) 6-Thioguanine (Tabloid®) Fludarabine (Fludara®) Cladribine (Leustatin®)     MOA: Inhibits DNA synthesis; Inhibits DNA polymerase alpha, DNA primase, and ribonucleotide reductase |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Purinethol®           Purine Analog (Antimetabolite) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Tabloid®           Purine Analog (Antimetabolite) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Fludara®           Purine Analog (Antimetabolite) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Leustatin®           Purine Analog (Antimetabolite) |  | 
        |  | 
        
        | Term 
 
        |       Mitosis Inhibitors Vinca Alkaloids |  | Definition 
 
        | Vinblastine Vincristine (Oncovin®) Vinorelbine (Navelbine®)     MOA: Inhibits microtubule formation, arresting mitosis in metaphase |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | No Brand Name           Vinca Alkaloids (Mitosis Inhibitor) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Oncovin®, Vincasar® PFS           Vinca Alkaloid (Mitosis Inhibitor) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Navelbine®           Vinca Alkaloid (Mitosis Inhibitor) |  | 
        |  | 
        
        | Term 
 
        |        Mitosis Inhibitors Taxanes  |  | Definition 
 
        | Paclitaxel (Taxol®) Nab-paclitaxel (Abraxane®) Docetaxel (Taxotere®) Carbazitaxel (Jevtana®)     MOA: Promotes formation and inhibits disassembly of stable microtubules, inhibiting mitosis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Taxol®           Taxane (Mitosis Inhibitor) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Abraxane®           Taxane (Mitosis Inhibitor) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Taxotere®           Taxane (Mitosis Inhibitor) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Jevtana®           Taxane (Mitosis Inhibitor) |  | 
        |  | 
        
        | Term 
 
        |       Mitosis Inhibitors Topoisomerase Inhibitors |  | Definition 
 
        | Etoposide (Etopophos®) Teniposide (Vumon®) Irinotecan (Camptosar®)     MOA: Binds to topoisomerase I-DNA complexes, preventing religationof single-strand breaks |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Etopophos®           Topoisomerase Inhibitor (Mitosis Inhibitor) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Vumon®           Topoisomerase Inhibitor (Mitosis Inhibitor) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Camptosar®             Topoisomerase Inhibitor (Mitosis Inhibitor) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Bleomycin (Blenoxane®) Dactinomycin (Actinomycin-D®) Mitomycin (Mutamycin®)     MOA: Inhibits DNA synthesis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Blenoxane®           Antitumor Antibiotic |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Actinomycin D®, Cosmegen®           Antitumor Antibiotic |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Mutamycin®           Antitumor Antibiotic |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Doxorubucin (Adriamycin®) Daunorubicin (Cerubidine®) Idarubicin (Idamycin® PFS) Epirubicin (Ellence®) Valrubicin (Valstar®) Mitoxantrone (Novantrone®)   MOA: Binds and intercalates into DNA, inhibiting nucleic acid and protein synthesis; triggers DNA cleavage by topoisomerase II |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Adriamycin®           Anthracycline |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Cerubidine®           Anthracycline |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Idamycin® PFS           Anthracycline |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Novantrone®             Anthracycline |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Tamoxifen (Soltamox®) Anastrozole (Arimidex®) Letrozole (Femara®)     MOA: Inhibits enzymatic androgen conversion to estrogen, reducing hormone receptor positive cancer cell growth |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Leuprolide (Lupron®) Goserelin (Zoladex®)     MOA: Inhibits gonadotropin release, suppressing ovarian and testicular steroidogenesis |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        |         Tyrosine Kinase Inhibitors |  | Definition 
 
        | Imatinib (Gleevec®) Sorafenib (Nexavar®) Vandetanib (Zactima®) Pazopanib (Votrient®) Gefitinib (Iressa®) Erlontinib (Tarceva®) Dasatinib (Sprycel®) Nilotinib (Tasigna®) Lapatinib (Tykerb®) Sunitinib (Sutent®)     MOA: Inhibits intracellular tyrosine kinase domain of epidermal growth factor receptor (EGFR), resulting in cell cycle arrest and angiogenesis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Gleevec®             Tyrosine Kinase Inhibitor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Nexavar®             Tyrosine Kinase Inhibitor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Zactima®             Tyrosine Kinase Inhibitor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Votrient®             Tyrosine Kinase Inhibitor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Iressa®             Tyrosine Kinase Inhibitor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Tarceva®             Tyrosine Kinase Inhibitor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Sprycel®           Tyrosine Kinase Inhibitor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Tasigna®             Tyrosine Kinase Inhibitor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Tykerb®           Tyrosine Kinase Inhibitor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Sutent®             Tyrosine Kinase Inhibitor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Interferon alfa-2a (Roferon®) Interferon alfa-2b (Intron A®) Interferon alfa-n3 (Alferon-N®) Aldesleukin (Proleukin®) Denileukin difitox (Ontak®) Bacillus Calmette-Guerin (BCG) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Roferon®     MOA: Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages and augments cytotoxicity of lymphocytes for target cells   Interferon (Immunotherapy) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Intron® A   MOA: Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages and augments cytotoxicity of lymphocytes for target cells   Interferon (Immunotherapy) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Alferon® N   MOA: Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages and augments cytotoxicity of lymphocytes for target cells   Interferon (Immunotherapy) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Proleukin®   MOA: Promotes proliferation, differentiation, and recruitment of T and B cells, natural killer cells, and thymocytes; causes cytolytic activity in a subset of lymphocytes and subsequent interactions stimulate the immune system and malignant cells; can stimulate lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL) cells   Immunotherapy |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Ontak®     MOA: Binds to high affinity IL-2 receptors, inhibits protein synthesis, resulting in cell death       Immunotherapy |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | BCG     MOA: cross reacts with cytotoxic cells to cause destruction     Immunotherapy |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Rituximab (Rituxan®) Gentuzumab (Mylotarg®) Bevacizumab (Avastin®) Cetuximab (Erbitux®) Trastuzumab (Herceptin®) Ranibizumab (Lucentis®) Panitumumab (Vectibix®)   MOA: Inhibits growth factor by binding to the outside of the cell |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Rituxan®             Monoclonal Antibody |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Mylotarg®           Monoclonal Antibody |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Avastin®           Monoclonal Antibody |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Erbitux®             Monoclonal Antibody |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Herceptin®             Monoclonal Antibody |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Lucentis®             Monoclonal Antibody |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Vectibix®             Monoclonal Antibody |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Chromic Phosphate Sodium Phosphate P32 Sodium Iodide I131 Strontium 89 Chloride Samarium SM 153 Lexidronam     None of these have brand names and he didn't state the mechanism of action |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Hydroxyurea (Hydrea®) Mitotane (Lysodren®) Tretinoin (Retin-A®) Alitretinoin (Panretin®)         |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Hydrea®     MOA: Inhibits ribonucleotide diphosphate reductase       Miscellaneous Agents |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Lysodren®     MOA: Supresses adrenal cotrex, modifies steroid metabolism       Miscellaneous Agent |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Retin-A®     MOA: Induces differentiation and decreases proliferative of APL cells       Miscellaneous Agent |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Parentin®     MOA: Binds to retionid receptors, inhibiting cell growth       Miscellaneous Agent |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Sorangium cellulosum Ixabepilone (Ixempra®)   MOA: Inhibits uritosis by the same mechanism as taxanes       |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        |         Drugs to Treat Nausea and Vomiting |  | Definition 
 
        | Prochlorperazine (Compazine®) Dronabinol (Marinol®) Nabilone (Cesamet®) Metoclopramide (Reglan®) Ondansetron (Zofran®) Granisetron (Kytril®) Dolasetron (Anzemet®) Palonsetron (Aloxi®) Aprepitant (Emend®) |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Marinol®             Cannabinoid Derivative |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        |         Drugs to Treat Hyperuricemia |  | Definition 
 
        | Allopurinol (Zyloprim®) Febuxostat (Uloric®)   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Zyloprim®             Xanthine Oxidase Inhibitor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Uloric®             Xanthine Oxidase Inhibitor |  | 
        |  | 
        
        | Term 
 
        |         Drugs Used with Chemotherapy |  | Definition 
 
        | Mesna (Mesnex®) Leucovorin (Wellcovorin®)   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Mesnex®     Used with cyclophosphamide and ifosfamide to prevent hemorrhagic cystitis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Wellcovorin®     Used with 5-FU and Methotrexate   |  | 
        |  |